Intech Investment Management 13F: Adds $7.9M to ABT Stake

Intech Investment Management has significantly increased its position in Abbott Laboratories (NYSE: ABT). According to the latest 13F filing with the SEC, the firm boosted its holdings by 93.99%, adding 87,218 shares. This brings Intech's total to 180,014 shares, valued at approximately $15.86 million as of the reporting period.

What Changed in Intech Investment Management's Abbott Laboratories Position

Intech Investment Management nearly doubled its stake in Abbott Laboratories during the latest quarter. The firm previously held 92,796 shares and increased this to 180,014 shares, reflecting a substantial addition of 87,218 shares. This move represents a 93.99% increase in their holdings, showcasing increased confidence in the company.

Other Institutional Activity in Abbott Laboratories

Other major institutional investors also made notable moves in Abbott Laboratories. BlackRock, Inc. reduced its position by 1,221,310 shares, ending with 145,687,458 shares valued at about $14.96 billion. Vanguard Capital Management LLC initiated its position with 112,949,933 shares worth approximately $11.60 billion. State Street Corp trimmed its holdings by 278,314 shares, leaving it with 79,575,468 shares valued at $8.17 billion. Meanwhile, Capital Research Global Investors added 10,606,123 shares to hold a total of 49,775,362 shares, valued at $5.11 billion.

Abbott Laboratories Stock Down 11.2%

Shares of Abbott Laboratories (NYSE: ABT) recently traded near $88.12. The company boasts a market cap of $153.59 billion and a P/E ratio of 24.7, with a forward P/E of 14.55. The stock's 52-week range is between $81.97 and $139.06, with a 50-day moving average of $91.22 and a 200-day moving average of $114.49. Abbott has a beta of 0.62, indicating lower volatility compared to the market.

Recent Earnings

Abbott Laboratories reported revenue of $45.13 billion, with a growth rate of 7.8%. The company achieved a net margin of 13.9% and a return on equity of 12.33%. Its earnings per share stood at $3.57. The next earnings report is expected on April 16, 2026.

Dividend

Abbott Laboratories pays an annual dividend of $2.52, yielding 2.86%. The dividend payout ratio is 67.23%, indicating a sustainable distribution relative to earnings.

Insider Buying and Selling at Abbott Laboratories

Several insiders have recently purchased shares of Abbott Laboratories. On April 28, 2026, Executive Vice President Mary Moreland bought 5,314 shares at an average price of $94.41. Daniel Starks acquired 10,000 shares on April 27 at $92.65, while on April 24, he purchased an additional 7,105 shares. Other insiders, including Nita Ahuja, Sally Blount, and John Stratton, also made smaller purchases on April 24.

Analysts Set New Price Targets

Several analysts have maintained their buy ratings on Abbott Laboratories. On April 20, 2026, Barclays set a price target of $143. Piper Sandler, Oppenheimer, RBC Capital, Benchmark, Evercore ISI Group, B of A Securities, and Stifel all maintained buy ratings with price targets ranging from $115 to $130 in mid-April. The consensus among 24 analysts is a 'buy', with a mean price target of $116.54.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois. It develops, manufactures, and sells a wide range of healthcare products, including medical devices, diagnostics, and nutritional products. The company operates in several segments, including Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Led by CEO Mr. Philip P. Boudreau, Abbott employs about 122,000 people worldwide.

Bottom Line

Intech Investment Management's significant increase in Abbott Laboratories shares underscores its growing confidence in the company. Investors closely monitor such institutional moves as they can indicate broader market sentiment. It's important to remember that 13F filings are historical and reflect past holdings, not necessarily current positions.